Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Anxiety Disorders 6Neoplasms 5Pain 4Sleep Initiation and Maintenance Disorders 3Prostatic Neoplasms 2Nausea 2Hematopoietic and Lymphatic System Neoplasm 2Breast Neoplasms 2Vomiting 1Skin Neoplasms 1Sarcoma 1Respiratory Aspiration 1Neuroblastoma 1Melanoma 1Lymphoma 1Leukemia 1Hodgkin Disease 1Gastrointestinal Neoplasms 1Fatigue 1Dyspnea 1Depression 1Colorectal Neoplasms 1Colonic Polyps 1Chemotherapy Effect 1Carcinoma, Neuroendocrine 1Brain Neoplasms 1Anorexia 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Aromatherapy × Clear all
NCT03858855 2020-08-04

Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment

Ohio State University Comprehensive Cancer Center

Phase NA Completed
248 enrolled
DermatologicEndocrineGastrointestinal

Gastrointestinal Neoplasms, Melanoma, Skin Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡